Silvia Boarino

Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

Jennifer K Quint, Sofie Arnetorp, Janwillem Kocks et al. · The Journal of Allergy and Clinical Immunology In Practice · 2022 · 73 citations · Full text

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel et al. · European Respiratory Journal · 2024 · 50 citations · Full text

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Francesco Menzella, Elena Bargagli, Maria Aliani et al. · Respiratory Research · 2022 · 40 citations · Full text

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Alessandra Vultaggio, Maria Aliani, Elena Altieri et al. · Respiratory Research · 2023 · 32 citations · Full text

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

Maria D’Amato, Francesco Menzella, Elena Altieri et al. · Frontiers in Allergy · 2022 · 25 citations · Full text